New York, USA, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Market Overview: The market for Zollinger-Ellison syndrome treatment is on a ...

The demand for organoids is being driven mainly by an increased preference for personalized medicine, a rising trend of using organoids as alternatives to animal testing, and their expanding ...

GlaxoSmithKline is investing in artificial intelligence (AI) with the hope of radically cutting the time and money needed to develop a drug. It has entered into an alliance with Exscientia, a new ...

GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Service Income and Other Operating Revenue for the year ending 31-Mar-2024.For the quarter ended 30-09-2024, ...